Form 4: Arrowhead CMO Sells $700K in Stock Under 10b5-1 Plan

James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, sold 20,000 shares of common stock for a weighted average price of $35.00 per share, totaling $700,000, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), reported a sale of common stock.
• The transaction involved 20,000 shares of common stock.
• The shares were sold on October 1, 2025, at a weighted average price of $35.00 per share, with prices ranging from $35.00 to $35.06.
• The total value of the shares sold was approximately $700,000.
• The sale was executed under a Rule 10b5-1 trading plan, adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following the transaction, Mr. Hamilton beneficially owns 212,122 shares of common stock directly.
• The reported beneficial ownership includes previously reported shares of common stock underlying Restricted Stock Units, a portion of which are still subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is a neutral event for the company's operational or financial outlook.

Positives

• No direct positives for the company's operational performance are indicated by this routine insider transaction.

Negatives

• No direct negatives for the company's operational performance are indicated by this routine insider transaction.

Risks

• NA

Future Outlook

NA

Industry Context

This filing reports a standard insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology sector.

Stakeholder Impact

• Shareholders should note the routine nature of this insider sale, executed under a 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify portfolios. It does not inherently signal a change in company fundamentals.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan. Such planned sales are common for executives managing personal finances and diversifying holdings and typically do not reflect a change in the company's fundamental prospects. Therefore, this filing alone does not warrant a change in investment recommendation, and a 'hold' stance is appropriate.

Keywords

Arrowhead Pharmaceuticals, ARWR, James C. Hamilton, Chief Medical Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction, Biotechnology